NMTrypI – “New Medicines for Trypanosomatidic Infections” is a research project funded by the Seventh Framework Programme of the European Union under Grant agreement number 603240.
The infectious diseases burden imposed by the
parasites of Trypanosomatidae family
represents a huge problem on people’s lives in countries where these diseases are endemic. Problems associated with existing drugs include inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. New drugs are urgently needed now and in the foreseeable future. The NMTrypI consortium uses a highly interdisciplinary approach (13 institutions from 9 countries) to optimize pteridine, benzothiazole and miltefosine derivatives, as well as natural products against Trypanosomatids.